论文部分内容阅读
目的探索重组5型腺病毒(rAd5)对卵清蛋白(OVA)诱发的小鼠哮喘模型的影响。方法 60只6~8周龄、体质量18~20 g的雌性C57BL/6小鼠被随机分为健康对照组、rAd5对照组、OVA哮喘对照组、rAd5处理的OVA哮喘组,每组15只。OVA哮喘对照组、rAd5处理的OVA哮喘组在第0、7、14天分别采用含50μg OVA和2 mg氢氧化铝混悬液腹腔注射致敏3次、于第42、43、44天连续3 d用OVA雾化激发制作哮喘模型。其余两组采用相同体积的生理盐水处理。rAd5对照组、rAd5处理的OVA哮喘组于实验第21天开始肌注rAd5(2.5×109个病毒颗粒/只)1次。并于第35天滴鼻加强1次rAd5(2.5×109个病毒颗粒/只)。所有小鼠于最后一次雾化激发48 h内进行安乐死。通过无创肺功能仪体描法检测小鼠气道高反应,收集血清及肺泡灌洗液标本、收集肺组织用于HE及PAS染色,通过ELISA检测肺泡灌洗液中的白细胞介素4(IL-4)、IL-5、IL-13及血清中的总IgE。结果与健康对照组及rAd5对照组相比,OVA哮喘对照组、rAd5处理的OVA哮喘组其肺部炎症及黏液分泌显著增加,其肺泡灌洗液中IL-4、IL-5、IL-13及血清中的总IgE含量显著增高,其气道高反应显著升高。然而,OVA哮喘对照组与rAd5处理的OVA哮喘组之间无显著差异。结论重组5型腺病毒作用于小鼠哮喘模型不会加重哮喘症状。
Objective To explore the effect of recombinant adenovirus type 5 (rAd5) on ovalbumin (OVA) -induced mouse asthma model. Methods Sixty female C57BL / 6 mice aged 6-8 weeks and weighing 18-20 g were randomly divided into healthy control group, rAd5 control group, OVA asthma control group and rAd5-treated OVA asthma group, 15 rats in each group . OVA asthma control group and rAd5-treated OVA asthma group were sensitized 3 times by intraperitoneal injection with 50μg OVA and 2 mg aluminum hydroxide suspension respectively on days 0, 7 and 14, and continued for 3, 42, 43 and 44 days d with OVA atomization to stimulate the production of asthma model. The remaining two groups were treated with the same volume of saline. The rAd5 control group and the rAd5-treated OVA asthma group were intramuscularly injected with rAd5 (2.5 × 10 9 virus particles / only) on the 21st day of the experiment. On day 35, rAd5 (2.5 × 10 9 virus particles / mouse) was administered intranasally once a day. All mice were euthanized within 48 h of the last nebulization challenge. The airway hyperresponsiveness in mice was detected by noninvasive pulmonary function method. Serum and alveolar lavage fluid samples were collected and the lung tissues were collected for HE and PAS staining. The level of interleukin-4 (IL- 4), IL-5, IL-13 and total IgE in serum. Results Compared with healthy control group and rAd5 control group, OVA asthma control group and rAd5-treated OVA asthma group had significantly increased lung inflammation and mucus secretion, and IL-4, IL-5 and IL-13 in BALF And serum total IgE levels were significantly increased, the airway hyperresponsiveness was significantly increased. However, there was no significant difference between the OVA asthma control group and the rAd5-treated OVA asthma group. Conclusion Recombinant adenovirus type 5 does not aggravate asthma symptoms in mouse asthma model.